Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.866,98
1,55%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PDS Biotechnology Corporation (PDSB) PDS Biotechnology Corporation (PDSB) Notizie

PDS Biotechnology Corporation

PDSB
3,89
0,16 (4,29%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/1/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202422:31EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/1/202423:10EDGAR2Form 8-K - Current report
22/1/202422:45GLOBEPDS Biotech Announces Retirement of Lauren V. Wood, M.D.,..
16/1/202414:00GLOBEPDS Biotech to Participate at B. Riley Securities 4th Annual..
04/12/202322:50GLOBEPDS Biotechnology Reports Inducement Grant Under Nasdaq..
04/12/202322:02EDGAR2Form 8-K - Current report
28/11/202313:30GLOBEPDS Biotech Appoints Lars Boesgaard as Chief Financial..
28/11/202312:02EDGAR2Form 8-K - Current report
14/11/202313:30GLOBEPDS Biotech Reports Third Quarter 2023 Financial Results and..
09/11/202322:07EDGAR2Form 8-K - Current report
09/11/202314:00GLOBEPDS Biotech Announces Updated Survival Data from NCI-Led..
07/11/202314:00GLOBEPDS Biotechnology Announces Conference Call and Webcast for..
23/10/202322:06EDGAR2Form 8-K - Current report
23/10/202314:00GLOBEPDS Biotech Announces Preliminary Biomarker Study Results in..
11/10/202322:02EDGAR2Form 8-K - Current report
11/10/202314:00GLOBEPDS Biotech Announces Interim Safety and Immune Response..
03/10/202322:03EDGAR2Form 8-K - Current report
03/10/202322:03EDGAR2Form 8-K - Current report
03/10/202315:02EDGAR2Form 8-K - Current report
03/10/202313:00GLOBEPDS Biotech Announces Interim 24-Month Survival Rate of 74%..
02/10/202322:05EDGAR2Form 8-K - Current report
02/10/202314:00GLOBEPDS Biotech Announces PDS0101 Combined with..
26/9/202314:00GLOBEPDS Biotech to Present at the LD Micro Main Event XVI
25/9/202314:00GLOBEPDS Biotech Reschedules Key Opinion Leader Roundtable..
20/9/202322:10EDGAR2Form 8-K - Current report
20/9/202322:05GLOBEPDS Biotech to Participate in the 2023 Cantor Fitzgerald..
20/9/202314:00GLOBEPDS Biotech Announces PDS0202 Elicits Active Neutralization..
13/9/202314:00GLOBEPDS Biotech to Host Key Opinion Leader Roundtable Addressing..
11/9/202322:05EDGAR2Form 8-K - Current report
08/9/202312:02EDGAR2Form 8-K - Current report
06/9/202322:05GLOBEPDS Biotech to Participate at the H.C. Wainwright 25th..
06/9/202314:00GLOBEPDS0202 Universal Influenza Preclinical Ferret Data to be..
18/8/202322:04EDGAR2Form 8-K - Current report
17/8/202322:05EDGAR2Form 8-K - Current report
16/8/202314:00GLOBEPDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial..
14/8/202322:05EDGAR2Form 8-K - Current report
14/8/202319:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202313:30GLOBEPDS Biotech Reports Second Quarter 2023 Financial Results..
14/8/202313:00GLOBEPDS Biotech Announces Submission of Phase 3 Protocol to FDA..
07/8/202314:00GLOBEPDS Biotechnology Announces Conference Call and Webcast for..
02/8/202314:00GLOBEPDS Biotech to Present at BTIG Virtual Biotechnology..
25/7/202322:01EDGAR2Form 8-K - Current report
25/7/202314:00GLOBEPDS Biotech to Present Immune Response Data from Combination..
17/7/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202323:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202323:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202323:24EDGAR2Form 8-K - Current report
17/7/202323:23EDGAR2Form 8-K - Current report
17/7/202314:00GLOBEPDS Biotech Announces Acceptance of Abstract on Combination..
Apertura: 3,85 Min: 3,74 Max: 3,96
Chiusura: 3,73

La tua Cronologia

NASDAQ
PDSB
PDS Biotechnology
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network